Skip to main content
Signal8

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026

$INCYPress releaseNov 4, 2026, 9:00 AM ETRead the release

Incyte will present more than 30 abstracts across its hematology portfolio at the ASH 2026 Annual Meeting, December 12-15 in New Orleans. Highlights include oral presentations of first-line myelofibrosis data for INCA033989, its first-in-class mutant calreticulin-targeted antibody, plus updated second-line MF and essential thrombocythemia results, and long-term Phase 1/2 data for latarcibart (VGA039) in von Willebrand disease. An investor and analyst event will be held Saturday, December 12, 2026, 7:30-9:00 p.m.

Key figures

Abstract count
more than 30
Investor event date
December 12, 2026, 7:30-9:00 p.m. CT

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    INCY: Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026 — AI Analysis | Signal8